High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Clinical Trials

10 clinical trials for High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Personalized NK Cell Therapy in CBT — RECRUITING · PHASE2
• Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma — RECRUITING · PHASE2
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia — RECRUITING · PHASE2
• Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma — RECRUITING
• Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL — RECRUITING · PHASE2
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia — COMPLETED · PHASE2
• NK Cells in Cord Blood Transplantation — OTHER · PHASE1

Refine this search